| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
SVP, Chief Financial Officer | Chief Financial Officer
3 companies
Dhingra Ankur serves as a Chief Financial Officer at SMMT and has filed Form 4s across 3 companies. Across recent SEC filings that breaks down to 8 buys and 0 sells. Those positions are worth an estimated $7.0M at current prices.
Historically, Dhingra Ankur's trades have earned a strong insider score of 70/100 across 6 rated trades. Over a 12-month horizon, 83.3% of those trades were profitable, with an average 12-month return of +64.0%.
The biggest single holding is ILMN (~$4.4M) as SVP, Chief Financial Officer. Net of sales, the recent Form 4 record there shows accumulation of 6,100 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| May 12, 2025 | ILMN Illumina, Inc. | SVP, Chief Financial Officer | Buy | 6,100 | $81.21 | $495,381.00 | +32.4% | +16.2% | +78.6% | |
| Mar 26, 2024 | SMMT Summit Therapeutics Inc. | Chief Financial Officer | Buy | 100,000 | $3.75 | $375,000.00 | +39.2% | +113.9% | +431.8% | |
| Dec 13, 2023 | SMMT Summit Therapeutics Inc. | Chief Financial Officer | Buy | 20,400 | $2.17 | $44,254.00 | +8.7% | +84.2% | +663.7% | |
| Mar 7, 2023 | SMMT Summit Therapeutics Inc. | Chief Financial Officer | Buy | 196,362 | $1.05 | $206,180.10 | +514.1% | +34.8% | +250.7% | |
| Aug 16, 2022 | SMMT Summit Therapeutics Inc. | Chief Financial Officer | Buy | 36,215 | $0.97 | $35,128.55 | +1,828% | +4.0% | +76.2% | |
| Nov 24, 2021 | CDNA Caredx, Inc. | Chief Financial Officer | Buy | 5,000 | $42.34 | $211,693.50 | New | -17.0% | -70.9% |